Uganda National Bureau of Standards can now offer ISO Certification

April 15, 2019 | 78 views

The Uganda National Bureau of Standards (UNBS) has been accredited by the South African National Accreditation System (SANAS) to provide International Organisation for Standardisation (ISO) Management Systems Certification. The accreditation comes at a time when a growing number of Ugandan companies are seeking ISO management systems certification to benefit from the nascent oil and gas sector. 

Spotlight

Harlem Biospace

Harlem Biospace (Hb) is a new biotech incubator, the first of its kind in New York City, to offer affordable shared wet-lab space for early-stage biotech companies. It offers a beautiful wet lab outfitted with modern biotech equipment, exciting classes and events, and business support – creating a community to turn ideas into inventions that solve real health problems. Harlem Biospace is situated at the heart of three academic campuses (Columbia University, City College of New York, and Columbia’s Manhattanville campus), with easy access to other major universities, the life science community, and the vibrancy of New York City.

OTHER ARTICLES
MEDTECH

Top 10 biotech IPOs in 2019

Article | October 7, 2022

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More
MEDTECH

Cell Out? Lysate-Based Expression an Option for Personalized Meds

Article | July 12, 2022

Cell-free expression (CFE) is the practice of making a protein without using a living cell. In contrast with cell line-based methods, production is achieved using a fluid containing biological components extracted from a cell, i.e., a lysate. CFE offers potential advantages for biopharma according to Philip Probert, PhD, a senior scientist at the Centre for Process Innovation in the U.K.

Read More
MEDICAL

Closing bacterial genomes from the human gut microbiome using long-read sequencing

Article | August 16, 2022

In our lab, we focus on the impact of the gut microbiome on human health and disease. To evaluate this relationship, it’s important to understand the particular functions that different bacteria have. As bacteria are able to exchange, duplicate, and rearrange their genes in ways that directly affect their phenotypes, complete bacterial genomes assembled directly from human samples are essential to understand the strain variation and potential functions of the bacteria we host. Advances in the microbiome space have allowed for the de novo assembly of microbial genomes directly from metagenomes via short-read sequencing, assembly of reads into contigs, and binning of contigs into putative genome drafts. This is advantageous because it allows us to discover microbes without culturing them, directly from human samples and without reference databases. In the past year, there have been a number of tour de force efforts to broadly characterize the human gut microbiota through the creation of such metagenome-assembled genomes (MAGs)[1–4]. These works have produced hundreds of thousands of microbial genomes that vastly increase our understanding of the human gut. However, challenges in the assembly of short reads has limited our ability to correctly assemble repeated genomic elements and place them into genomic context. Thus, existing MAGs are often fragmented and do not include mobile genetic elements, 16S rRNA sequences, and other elements that are repeated or have high identity within and across bacterial genomes.

Read More

Selexis Cell Line Development Strategies

Article | February 11, 2020

In today’s biotechnology landscape, to be competitive, meet regulations, and achieve market demands, “we must apply Bioprocessing 4.0,” said Igor Fisch, PhD, CEO, Selexis. In fact, in the last decade, “Selexis has evolved from cloning by limiting dilution to automated cell selection to nanofluidic chips and from monoclonality assessment by statistical calculation to proprietary bioinformatic analysis,” he added. Single-use processing systems are an expanding part of the biomanufacturing world; as such, they are a major component of Bioprocessing 4.0. “At Selexis, we use single use throughout our cell line development workflow. Currently, we have incorporated single-use automated bioprocessing systems such as ambr® and the Beacon® optofluidic platform for accelerated cell line development. By using these systems and optimizing our parameters, we were able to achieve high titers in shake flasks. Additionally, the Beacon systems integrate miniaturized cell culture with high-throughput liquid handling automation and cell imaging. This allows us to control, adjust, and monitor programs at the same time,” noted Fisch.

Read More

Spotlight

Harlem Biospace

Harlem Biospace (Hb) is a new biotech incubator, the first of its kind in New York City, to offer affordable shared wet-lab space for early-stage biotech companies. It offers a beautiful wet lab outfitted with modern biotech equipment, exciting classes and events, and business support – creating a community to turn ideas into inventions that solve real health problems. Harlem Biospace is situated at the heart of three academic campuses (Columbia University, City College of New York, and Columbia’s Manhattanville campus), with easy access to other major universities, the life science community, and the vibrancy of New York City.

Related News

Severity of COVID-19 May Depend on Your Individual Genetic Variation in Immune System

SciTechDaily | April 19, 2020

Genetic variability in the human immune system may affect susceptibility to, and severity of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus disease (COVID-19). The research is published on April 17, 2020, in the Journal of Virology, a publication of the American Society for Microbiology. Individual genetic variation may explain differences in the strength of immune responses. Certain immune system genes, called human leukocyte antigen genes that are involved in recognizing pathogens, vary from person to person. Variations can influence how well the immune system recognizes a given pathogen. Poor recognition of SARS-CoV-2 could cause a person to be more vulnerable to the virus. “In particular, understanding how variation in HLA [a component of the immune system containing multiple genes] may affect the course of COVID-19 could help identify individuals at higher risk from the disease,” according to the authors of the new study.

Read More

Biotech stocks surge as people are hungry for good news on the coronavirus

cnbc | April 17, 2020

Biotech stocks surged Friday after new details on a closely watched clinical trial lifted hopes that scientists may be close to a treatment for the coronavirus, which continues to maintain its foothold across the globe after emerging a little over three months ago.The IBB, an ETF that tracks biotech’s biggest players, was up more than 2% Friday after health-care publication STAT News revealed early impressions from one of Gilead Sciences’ clinical trials for antiviral drug remdesivir. The University of Chicago found that patients with Covid-19 had “rapid recoveries in fever and respiratory symptoms” and were discharged in less than a week, according to STAT. News that biotech firm Moderna received $483 million in federal funds for its vaccine development also boosted the sector higher.

Read More

Selected Notes From Wall Street Analysts On Applied DNA Sciences, Inc. (APDN)

US Post News | April 16, 2020

On Wednesday, shares of Applied DNA Sciences, Inc. (NASDAQ:APDN) marked $5.76 per share versus a previous $4.55 closing price. With having a 26.59% gain, an insight into the fundamental values of Applied DNA Sciences, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. APDN showed a rise of 37.47% within its YTD performance, with highs and lows between $2.52 – $33.60 during the period of 52 weeks, compared to the simple moving average of -26.60% in the period of the last 200 days. Maxim Group equity researchers changed the status of Applied DNA Sciences, Inc. (NASDAQ: APDN) shares to a “Buy” rating in the report published on November 14th, 2016. Other analysts, including Maxim Group, also published their reports on APDN shares. Maxim Group repeated the rating from the previous report, marking APDN under “Buy” rating, in the report published on May 13th, 2016. Additionally, APDN shares got another “Buy” rating from Maxim Group, setting a target price of $13 on the company’s shares, according to the report published in October 8th, 2015.

Read More

Severity of COVID-19 May Depend on Your Individual Genetic Variation in Immune System

SciTechDaily | April 19, 2020

Genetic variability in the human immune system may affect susceptibility to, and severity of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus disease (COVID-19). The research is published on April 17, 2020, in the Journal of Virology, a publication of the American Society for Microbiology. Individual genetic variation may explain differences in the strength of immune responses. Certain immune system genes, called human leukocyte antigen genes that are involved in recognizing pathogens, vary from person to person. Variations can influence how well the immune system recognizes a given pathogen. Poor recognition of SARS-CoV-2 could cause a person to be more vulnerable to the virus. “In particular, understanding how variation in HLA [a component of the immune system containing multiple genes] may affect the course of COVID-19 could help identify individuals at higher risk from the disease,” according to the authors of the new study.

Read More

Biotech stocks surge as people are hungry for good news on the coronavirus

cnbc | April 17, 2020

Biotech stocks surged Friday after new details on a closely watched clinical trial lifted hopes that scientists may be close to a treatment for the coronavirus, which continues to maintain its foothold across the globe after emerging a little over three months ago.The IBB, an ETF that tracks biotech’s biggest players, was up more than 2% Friday after health-care publication STAT News revealed early impressions from one of Gilead Sciences’ clinical trials for antiviral drug remdesivir. The University of Chicago found that patients with Covid-19 had “rapid recoveries in fever and respiratory symptoms” and were discharged in less than a week, according to STAT. News that biotech firm Moderna received $483 million in federal funds for its vaccine development also boosted the sector higher.

Read More

Selected Notes From Wall Street Analysts On Applied DNA Sciences, Inc. (APDN)

US Post News | April 16, 2020

On Wednesday, shares of Applied DNA Sciences, Inc. (NASDAQ:APDN) marked $5.76 per share versus a previous $4.55 closing price. With having a 26.59% gain, an insight into the fundamental values of Applied DNA Sciences, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. APDN showed a rise of 37.47% within its YTD performance, with highs and lows between $2.52 – $33.60 during the period of 52 weeks, compared to the simple moving average of -26.60% in the period of the last 200 days. Maxim Group equity researchers changed the status of Applied DNA Sciences, Inc. (NASDAQ: APDN) shares to a “Buy” rating in the report published on November 14th, 2016. Other analysts, including Maxim Group, also published their reports on APDN shares. Maxim Group repeated the rating from the previous report, marking APDN under “Buy” rating, in the report published on May 13th, 2016. Additionally, APDN shares got another “Buy” rating from Maxim Group, setting a target price of $13 on the company’s shares, according to the report published in October 8th, 2015.

Read More

Events